| 95.59 -1.9 (-1.95%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 116.13 |
1-year : | 123.95 |
| Resists | First : | 99.42 |
Second : | 106.12 |
| Pivot price | 100.87 |
|||
| Supports | First : | 88.58 |
Second : | 73.7 |
| MAs | MA(5) : | 98.83 |
MA(20) : | 100.12  |
| MA(100) : | 103.35 |
MA(250) : | 94.08 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 34.2 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 117.71 | Low : | 78.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LMAT ] has closed below the lower bollinger band by 1.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ LMAT ] is to continue within current trading range. Bollinger Bands are 25.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 100.74 - 101.44 | 101.44 - 101.99 |
| Low: | 93.49 - 94.42 | 94.42 - 95.13 |
| Close: | 94.32 - 95.56 | 95.56 - 96.52 |
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Sat, 25 Jul 2026
LeMaitre Vascular, Inc. Revenue Breakdown – NASDAQ:LMAT - TradingView
Fri, 24 Jul 2026
LMAT|LeMaitre Vascular Inc|Price:98.390|Chg%:+0.900 - TradingKey
Fri, 24 Jul 2026
LMAT|LeMaitre Vascular Inc|Price:97.100|Chg%:-0.390 - TradingKey
Fri, 24 Jul 2026
First Trust Advisors LP Acquires 57,931 Shares of LeMaitre Vascular, Inc. $LMAT - MarketBeat
Sat, 18 Jul 2026
Copeland Capital Management LLC Has $95.05 Million Stock Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat
Tue, 14 Jul 2026
LeMaitre Vascular to Report Second Quarter 2026 Financial Results on August 4 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 23 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 100.6 (%) |
| Shares Short | 1,360 (K) |
| Shares Short P.Month | 1,190 (K) |
| EPS | 2.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.79 |
| Profit Margin | 24.3 % |
| Operating Margin | 26.7 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 16.5 % |
| Qtrly Rev. Growth | 11.1 % |
| Gross Profit (p.s.) | 8 |
| Sales Per Share | 11.21 |
| EBITDA (p.s.) | 3.44 |
| Qtrly Earnings Growth | 41.7 % |
| Operating Cash Flow | 87 (M) |
| Levered Free Cash Flow | 53 (M) |
| PE Ratio | 35.14 |
| PEG Ratio | 2.8 |
| Price to Book value | 5.37 |
| Price to Sales | 8.52 |
| Price to Cash Flow | 25.01 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|